Table 1 Demographic characteristics of HIV/AIDS patients at ART initiation
Demographic characteristics | Total n (%) | ADE group n (%) | Non-ADE group n (%) | χ2 | P |
|---|---|---|---|---|---|
Total | 6757 | 1139 | 5618 | Â | Â |
Age | 39.41 | < 0.001 | |||
 ≤ 40 | 2108 (31.2) | 279 (24.50) | 1829 (32.56) |  |  |
 40<age ≤ 65 | 3734 (55.26) | 724 (63.56) | 3010 (53.58) |  |  |
 > 65 | 915 (13.54) | 136 (11.94) | 779 (13.87) |  |  |
Gender | 48.23 | < 0.001 | |||
 Male | 4619 (68.36) | 878 (77.09) | 3741 (66.59) |  |  |
 Female | 2138 (31.64) | 261 (22.91) | 1877 (33.41) |  |  |
Marital status | 1.766 | 0.414 | |||
 Unmarried | 715 (10.58) | 109 (9.57) | 606 (10.79) |  |  |
 Married or living with a partner | 5026 (74.38) | 851 (74.71) | 4175 (74.31) |  |  |
 Divorced or widowed or other | 1016 (15.04) | 179 (15.72) | 837 (14.9) |  |  |
Route of HIV infection | 11.094 | 0.004 | |||
 Blood or plasma transfusion | 352 (5.21) | 45 (3.95) | 307 (5.46) |  |  |
 Sexual transmission | 6104 (90.34) | 1059 (92.98) | 5045 (89.80) |  |  |
 Other or unknown | 301 (4.45) | 35 (3.07) | 266 (4.73) |  |  |
WHO clinical stage | 1507.914 | < 0.001 | |||
 I | 2518 (37.27) | 74 (6.50) | 2444 (43.50) |  |  |
 II | 1138 (16.84) | 125 (10.97) | 1013 (18.03) |  |  |
 III | 1867 (27.63) | 290 (25.46) | 1577 (28.07) |  |  |
 IV | 1234 (18.26 | 650 (57.07) | 584 (10.40) |  |  |
Previous use of the cotrimoxazole | 580.705 | < 0.001 | |||
 Yes | 1879 (27.81) | 649 (56.98) | 1230 (21.89) |  |  |
 No | 4878 (72.19) | 490 (43.02) | 4388 (87.11) |  |  |
Initial antiretroviral regimen | 0.61 | 0.737 | |||
 2NRTIs + 1NNRTI | 5943 (87.95) | 1002 (87.97) | 4941 (87.95) |  |  |
 2NRTIs + 1PI | 517 (7.65) | 83 (7.29) | 434 (7.73) |  |  |
 Single or two drugs | 297 (4.4) | 54 (4.74) | 243 (4.33) |  |  |
Baseline CD4+ cell count (cells/μL) | 721.107 | < 0.001 | |||
 CD4 < 50 | 1900 (28.12) | 675 (59.26) | 1225 (21.80) |  |  |
 50 ≤ CD4 < 100 | 796 (11.78) | 137 (12.03) | 659 (11.73) |  |  |
 100 ≤ CD4 < 200 | 1430 (21.16) | 169 (14.84) | 1261 (22.45) |  |  |
 200 ≤ CD4 < 350 | 1796 (26.57) | 119 (10.45) | 1677 (29.85) |  |  |
 CD4 ≥ 350 | 835 (12.36) | 39 (3.42) | 796 (14.17) |  |  |
Duration of follow-up (years)a | 4.00 (1.92–6.50) | 3.58 (1.75–6.00) | 4.17 (2.00–6.58) | 3.64 | < 0.001 |